logo

FDA Calendar

Share
PDUFA dates and FDA Panel Review dates are very important because they are make or break events for biostocks when the decisions are announced. Also, usually biostocks experience a run-up going into the scheduled decision/review dates. So having prior knowledge of the catalysts goes a long way toward maximizing profit or minimizing loss while trading volatile biotech stocks.
Listed below are large cap, mid cap and small cap stocks with pending regulatory catalysts.

Get in-depth analysis and insight on investing in the high-stakes biotech and pharma sectors. Check out our premium biotech research product and our biotech home page.
Company Name
Ticker
Drug
Event
Date
Outcome
Details
Sanofi
Praluent (sBLA)
FDA decision to include the effect of Praluent in reducing overall risk of major adverse cardiovascular events
04/28/2019
Regeneron Pharmaceuticals
Praluent (sBLA)
FDA decision to include the effect of Praluent in reducing overall risk of major adverse cardiovascular events
04/28/2019
ADMA BIOLOGICS, INC.
RI-002 (BLA resubmission)
FDA decision on RI-002 to treat primary immune deficiency disease
04/02/2019
Evoke Pharma, Inc.
Gimoti (NDA)
FDA decision on Gimoti for the relief of symptoms in adult women with acute and recurrent diabetic gastroparesis
04/01/2019
Recro Pharma Inc.
Resubmitted IV Meloxicam (NDA)
FDA decision on resubmitted IV Meloxicam for management of moderate to severe pain
03/24/2019
Lexicon Pharmaceuticals Inc.
Sotagliflozin (NDA)
FDA decision on Sotagliflozin for type 1 diabetes
03/22/2019
Sanofi
Sotagliflozin (NDA)
FDA decision on Sotagliflozin for type 1 diabetes
03/22/2019
Aerie Pharmaceuticals, Inc.
Roclatan (NDA)
FDA decision on Roclatan for patients with open-angle glaucoma, retina diseases
03/14/2019
Roche Holding AG
Tecentriq (sBLA)
FDA decision on Tecentriq in Combination with Abraxane for Initial Treatment of People with PD-L1-Positive, Metastatic Triple-Negative Breast Cancer
03/12/2019
Bausch Health Companies Inc.
BHC, BHC.TO
Loteprednol etabonate ophthalmic gel (NDA)
FDA decision on Loteprednol etabonate ophthalmic gel for post-operative inflammation and pain following ocular surgery
02/25/2019
Alexion Pharmaceuticals Inc.
ALXN1210 (BLA)
FDA decision on ALXN1210 for the treatment of patients with paroxysmal nocturnal hemoglobinuria
02/18/2019
MOTIF BIO PLC
Iclaprim (NDA)
FDA decision on Iclaprim for acute bacterial skin and skin structure infections
02/13/2019
Evolus Inc.
DWP-450(Resubmitted BLA)
FDA decision on DWP-450 for treatment of moderate to severe glabellar lines
02/02/2019
Alkermes plc
ALKS 5461 (NDA)
FDA’s final decision on ALKS 5461 for adjunctive treatment of major depressive disorder
01/31/2019
Aquestive Therapeutics Inc.
APL-130277 (NDA)
FDA decision on APL-130277 to overcome episodic off periods in Parkinson's disease
01/29/2019


pharma-020518_14nov18.jpg Today's Daily Dose brings you news about AbbVie's uterine fibroids trial results; Apollo Medical's third quarter financial results; Aldeyra Therapeutics' anticipated milestones; Axsome's progress in its ASCEND trial; BELLUS Health's near-term catalyst, and FDA panel's vote on Mallinckrodt's MNK-812.
weekahead-nov09.jpg Clinical trial data is an important catalyst, and any update on the clinical studies can send the biotech stocks soaring or stumbling depending upon the news. Here are some of the pharma/biotech stocks to watch out for in the week starting November 12.
pharma-021317_07nov18.jpg Today's Daily Dose brings you news about the near-term catalysts of Catalyst Pharma; progress in Entasis' gonorrhea study; positive results of Foamix Pharma's phase III papulopustular rosacea studies; Lannett's revised revenue outlook; NantKwest's cancer vaccine trial results; Nu Skin Enterprises' Q3 financial results and Rennova Health's reverse stock split.
Read More